Gilead Sciences, Inc. (LON:0QYQ)

Market Cap	108.91B
Revenue (ttm)	21.07B
Net Income (ttm)	4.61B
Shares Out	n/a
EPS (ttm)	3.66
PE Ratio	23.64
Forward PE	13.85
Dividend	2.38 (2.04%)
Ex-Dividend Date	Sep 15, 2025

Volume	1,364
Average Volume	5,777
Open	117.60
Previous Close	117.40
Day's Range	116.61 - 118.86
52-Week Range	84.17 - 121.83
Beta	0.35
RSI	58.76
Earnings Date	Nov 6, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 17,600
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QYQ

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD